Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peptic Ulcer01:27

Peptic Ulcer

Peptic ulcers are erosive lesions of the gastric or duodenal lining, most commonly caused by Helicobacter pylori infection. This Gram-negative, helical bacterium has adapted to survive the stomach’s acidic environment by producing urease, which converts urea into ammonia and carbon dioxide. The ammonia neutralizes gastric acid in the bacterium’s immediate environment, allowing colonization of the gastric mucosa. H. pylori attaches to mucus-secreting epithelial cells, penetrates the mucus...
Gastritis II: Pathophysiology01:26

Gastritis II: Pathophysiology

The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
Peptic Ulcer Disease III: Clinical Manifestations and Complications01:25

Peptic Ulcer Disease III: Clinical Manifestations and Complications

Duodenal UlcersDuodenal ulcers are the most common form of peptic ulcer disease, presenting with chronic, intermittent epigastric pain. Pain typically appears 2–3 hours after meals, especially when the stomach is empty, often waking patients at night. It is characteristically relieved by food or antacids (“pain–food–relief”). Some patients remain asymptomatic until complications like bleeding or perforation emerge, particularly with NSAID or anticoagulant use.Gastric UlcersGastric ulcers share...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gut Microbial, Inflammatory and Metabolic Signatures in Older People with Physical Frailty and Sarcopenia: Results from the BIOSPHERE Study.

Nutrients·2020
Same author

Safety of antithrombotic therapy in subjects with hereditary hemorrhagic telangiectasia: prospective data from a multidisciplinary working group.

Orphanet journal of rare diseases·2019
Same author

Stool for fecal microbiota transplantation should be classified as a transplant product and not as a drug.

United European gastroenterology journal·2019
Same author

Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer.

Mediators of inflammation·2019
Same author

Oral supplementation with lactobacilli to prevent colorectal cancer in preclinical models.

Minerva gastroenterologica e dietologica·2019
Same author

Autism, Gastrointestinal Symptoms and Modulation of Gut Microbiota by Nutritional Interventions.

Nutrients·2019
Same journal

Active Helicobacter pylori Infection and Survival Outcomes in De Novo Metastatic Colorectal Cancer: A Retrospective Cohort Study.

Helicobacter·2026
Same journal

Current Status of Diagnosis, Treatment, and Prevention of Helicobacter pylori Infection in China: A 2024-2025 National Multicenter Cross-Sectional Study.

Helicobacter·2026
Same journal

Worldwide Phylogenetic and Clinical Risk Association of the Helicobacter pylori Outer Membrane Gene hopQ.

Helicobacter·2026
Same journal

Global Diversity of Helicobacter pylori Prophages Reveals Genetic Drivers of Virulence and Associations With Gastric Cancer.

Helicobacter·2026
Same journal

How to Improve Patient Adherence During Helicobacter pylori Diagnosis and Treatment.

Helicobacter·2026
Same journal

Efficacy and Safety of Tegoprazan-Based Dual, Triple, and Quadruple Therapies in First-Line Helicobacter pylori Eradication: A Prospective Randomized Controlled Trial.

Helicobacter·2026
See all related articles

Related Experiment Video

Updated: Jun 20, 2026

Mouse Models Of Helicobacter Infection And Gastric Pathologies
07:43

Mouse Models Of Helicobacter Infection And Gastric Pathologies

Published on: October 18, 2018

Helicobacters and extragastric diseases.

Rinaldo Pellicano1, Francesco Franceschi, Giorgio Saracco

  • 1Department of Gastro-Hepatology, Molinette Hospital, Turin, Italy.

Helicobacter
|August 29, 2009
PubMed
Summary
This summary is machine-generated.

Helicobacter pylori infection is linked to extragastric conditions like idiopathic thrombocytopenic purpura (ITP) and sideropenic anemia. Eradicating H. pylori shows promise in treating these conditions, particularly ITP.

More Related Videos

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

Related Experiment Videos

Last Updated: Jun 20, 2026

Mouse Models Of Helicobacter Infection And Gastric Pathologies
07:43

Mouse Models Of Helicobacter Infection And Gastric Pathologies

Published on: October 18, 2018

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

Area of Science:

  • Microbiology
  • Gastroenterology
  • Immunology

Background:

  • Helicobacter pylori (H. pylori) has been implicated in numerous extragastric manifestations for 20 years.
  • The etiological role of H. pylori in many of these conditions remains under investigation due to epidemiological and disease-specific factors.

Purpose of the Study:

  • To review recent findings on H. pylori associations with extragastric manifestations.
  • To highlight the most compelling evidence for H. pylori's role in specific diseases.

Main Methods:

  • Literature review focusing on studies published within the last year.
  • Analysis of epidemiological data and clinical outcomes related to H. pylori infection and extragastric diseases.

Main Results:

  • Strong evidence supports H. pylori's role in idiopathic thrombocytopenic purpura (ITP) and sideropenic anemia.
  • Long-term follow-up indicates that 50% of ITP patients achieve hematological response after H. pylori eradication.
  • Emerging, though not conclusive, evidence suggests a link between H. pylori and ischemic heart disease.

Conclusions:

  • H. pylori eradication is a viable therapeutic strategy for H. pylori-associated ITP and sideropenic anemia.
  • Further research is needed to confirm the role of H. pylori in other extragastric diseases like ischemic heart disease.